Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade

NCT01658150 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.

NCT NCT01658150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01658150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade
Lead sponsor
Icahn School of Medicine at Mount Sinai
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2012
Completion date
January 2, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia